177Lu-BRP-010030

N/A

Report date: 2026/01/27 10:54:53

NME

Base Information

Drug Name177Lu-BRP-010030

Drug Alias Name177Lu-BRP-010030177LuBRP010030

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBoomRay Pharmaceuticals Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBoomRay Pharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A